Top Ten most popular articles on this week

pharmafile | July 12, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Pfizer, Sanofi, Trump, top 10 

In the week leading up to Donald Trump’s visit to the United Kingdom, the news has been dominated by the US president whose clashes with the Pfizer have hit the headlines. Meanwhile Pfizer announced plans to restructure the company while Sanofi shut down a plant in the Pyrenees. However, while the EMA released a survey identifying gaps in the pharmaceutical industry’s preparedness for Brexit, Scotland offered hope to patients of the deadly form of cancer RCC, through the approval of a new first line treatment.

Check out the week’s ten most popular articles on now!

10. MSD’s ulcerative colitis drug scores expanded indication in Europe

New Jersey-based multinational MSD have announced that the European Commission (EC) has approved Simponi (golimumab) for early dose optimisation in ulcerative colitis (UC) for patients with body weight less than 80kg who do not respond adequately to induction therapy.

9. Trump forces Pfizer to back down and delay price hikes until 2019

Following his call-out of Pfizer after the US pharma giant ignored the President’s threats to crack down on drug prices and raised the price of 100 of its drugs, the firm has confirmed it will delay planned price hikes until the beginning of next year.

8. EMA survey identifies gaps in pharma industry’s preparedness for Brexit

An EMA survey has identified gaps in the pharmaceutical industry’s preparedness for Brexit, finding that only 58% of market authorisation holders are on track with their regulatory planning in preparation for the UK’s exit from the European Union in March 2019. 

7. Sanofi shut down French plant over “astronomical” emission levels

Sanofi announced yesterday that they have stopped production at their plant in the French Pyrenees following complaints that the factory has been “sending astronomical quantities of pollutants into the air.”

6. Pfizer restructures in preparation for potential sell off

Pfizer has announced plans to reorganise into three separate units through the separation of its consumer health care business from the other two arms of the company.

5. Trump slams Pfizer over price hikes, Pfizer responds

Trump lashed out at Pfizer over Twitter following its price hiking of 100 of its products, and the pharma giant has defended itself.

4. Teva to relocate US HQ to New Jersey, affecting over 1,000 jobs

Teva has announced plans to relocate its North American headquarters from its current base in Philadelphia to Parsippany-Troy Hills, New Jersey, attracted by the state’s promise of $40 million in tax breaks.

3. Insider Interview: Biosimilars to balance the books

Jean-Yves Brault, Country Manager at Mylan UK, discusses how biosimilars are going to play an important role in driving down healthcare costs in the UK and how his company’s new product, Brabio, is faring in the market for the treatment of those with multiple sclerosis.

2. Novartis pulls out of antibiotics, cuts 140 staff

Novartis has announced that it is to terminate its research operations into antibiotics and antivirals in a reorganisation effort that will see 140 staff cut from the company.

1. Scotland approves first-line treatment for advanced kidney cancer

The Scottish Medicines Consortium has approved the use of EUSA Pharma’s Fotivda (tivozanib) as a first-line treatment for people with advanced renal cell carcinoma (RCC).

Related Content

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Latest content